| Chuck Hung Gee, PA-C | |
|
1868 W 9800 S Ste 100, South Jordan, UT 84095-4713 | |
| (801) 433-2873 | |
| (801) 433-5734 |
| Full Name | Chuck Hung Gee |
|---|---|
| Gender | Male |
| Speciality | |
| Experience | Years |
| Location | 1868 W 9800 S Ste 100, South Jordan, Utah |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1972620417 | NPI | - | NPPES |
| 287096-1206 | Other | UT | UTAH LICENSE NUMBER |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 287096-1206 (Utah) | Secondary |
| 363A00000X | Physician Assistant | 287096-1206 (Utah) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Chuck Hung Gee, PA-C 1868 W 9800 S Ste 100, South Jordan, UT 84095-4713 Ph: (801) 433-2873 | Chuck Hung Gee, PA-C 1868 W 9800 S Ste 100, South Jordan, UT 84095-4713 Ph: (801) 433-2873 |
News Archive
Scientists at the Institute of Bioengineering and Nanotechnology (IBN) and IBM Research – Almaden have developed the first biodegradable polymer nanoparticles to combat drug-resistant superbugs, such as Methicillin-Resistant Staphylococcus aureus (MRSA). These nanoparticles can selectively kill the bacteria without destroying healthy red blood cells, and being biodegradable, have great potential to treat infectious diseases in the body. This was reported today in the leading scientific journal, Nature Chemistry [(2011) DOI: 10.1038/nchem.1012].
MEDIAN Technologies, the leading provider of clinical applications for quantitative management of treatment responses in oncology imaging, today announced that it had obtained "Innovative Company" accreditation from OSEO (the French state innovation agency). This accreditation enables innovation-focused French investment funds (Fonds Communs de Placement dans l'Innovation) to invest in MEDIAN Technologies and enjoy a number of fiscal advantages.
Researchers from the University of Gothenburg and Sahlgrenska University Hospital are the first in the world to show that an operation can help patients with dementia caused by white matter changes and hydrocephalus.
Neoprobe Corporation, a diversified developer of innovative biomedical surgical oncology products, today announced consolidated results for the first quarter of 2010. First quarter 2010 revenues were $2.7 million, consistent with the record revenue reported for the first quarter of 2009.
Mary E. Jones, MD, MPH, is the child advocacy program director and an essential part of the Loyola University Health System pediatric team. In addition to her extensive knowledge in the medical care of children, her expertise in understanding the signs of child maltreatment help Loyola provide complete care to some of the most at-risk patients.
› Verified 2 days ago